Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs
Antimicrobial resistance, the so-called <i>silent pandemic</i>, is pushing industry and academia to find novel antimicrobial agents with new mechanisms of action in order to be active against susceptible and drug-resistant microorganisms. In the case of tuberculosis, the need of novel an...
Main Authors: | José Manuel Ezquerra-Aznárez, Pedro E. Almeida da Silva, José A. Aínsa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/9/11/2335 |
Similar Items
-
Double Repositioning: Veterinary Antiparasitic to Human Anticancer
by: Tania Sultana, et al.
Published: (2022-04-01) -
Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite <i>Schistosoma mansoni</i>
by: Raquel Porto, et al.
Published: (2021-07-01) -
Repurposing antifungal drugs for cancer therapy
by: Ningna Weng, et al.
Published: (2023-06-01) -
Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approach
by: Lalu Muhammad Irham, et al.
Published: (2022-12-01) -
Evaluating the Antiparasitic Activity of Novel BPZ Derivatives Against <i>Toxoplasma gondii</i>
by: Olivia Hatton, et al.
Published: (2020-07-01)